GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2008

Investors Commit $49.3M to Cadence Pharmaceuticals

  • Cadence Pharmaceuticals could raise up to $49.34 million through a registered stock offering to private investors. The transaction is expected to close on February 20.

    According to the shelf registration statement, private backers will purchase up to 9,240,307 shares of the company’s common stock at $5.34 per share, yesterday’s closing price.

    The total number of shares to be sold in the offering may be reduced to 8,056,716 under NASDAQ rules. Gross proceeds may thus go down to $43.0 million.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?